China’s Hengrui Pharma surges over 37% in Hong Kong debut

Published 23/05/2025, 04:18
© Reuters.

Investing.com-- Shares of Jiangsu Hengrui Pharmaceuticals Co (HK:1276) soared more than 37% in their Hong Kong trading debut on Friday, following the company’s $1.27 billion initial public offering priced at the top of its range.

The stock opened at HK$57.10, a 29.6% premium over the offer price of HK$44.05, and climbed as high as HK$60.20 in early trading, reflecting strong investor demand.

Hengrui, already listed in Shanghai, is among China’s leading drugmakers, with a focus on oncology and innovative therapies.

The company plans to use the proceeds to fund clinical trials, expand production capacity, and support international expansion efforts.

The robust debut comes amid a rebound in Hong Kong’s IPO market, which has seen increased activity from mainland Chinese firms seeking dual listings to attract global investors.

Earlier this week, Contemporary Amperex Technology Co Ltd (CATL) (HK:3750) debuted in Hong Kong, and saw its shares surge.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.